(2S,2'S)-N,N'-((1S,3R,4S,5R,6R)-4-(((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)bis(4-amino-2-hydroxybutanamide); 1,3-Di-HABA Kanamycin A; 4-O-(3-amino-3-deoxy-?-Dglucopyranosyl)-6-O-(6-amino-6-deoxy-?-D-glucopyranosyl)-1,3-N-bis[(2S)-4-amino-2-hydroxybutanoyl]-2-deoxy-Lstreptamine; O-3-Amino-3-deoxy-?-D-glucopyranosyl-(1?6)-O-[6-amino-6-deoxy-?-D-glucopyranosyl-(1?4)]-N1,N3-bis[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-D-streptamine
Amikacin EP Impurity B is a fully characterized chemical compound used as a reference standard of API Amikacin. The standard offered is compliant with regulatory guidelines. Amikacin EP Impurity B is used for analytical method development, method validation (AMV), and Quality Controlled (QC) applications during synthesis and formulation stages of drug development and serves as a reference standard for traceability against pharmacopeial standards (USP or EP). Axios Research products are intended for analytical purposes only and are not for human use. CAS - 927821-99-6
